Yearly Archives: 2020

Feb,11, 2020: Fennec Pharmaceuticals announced it has completed its rolling submission of an NDA to the U.S. FDA for PEDMARK™ (a unique formulation of sodium thiosulfate)...

Feb 10, 2020: Roche announced that the gantenerumab arm of the Phase II/III DIAN-TU-001 study did not meet its primary endpoint in the people...

Feb 10, 2020: Appraisal reports have been published for THE two medicines to treat exceptionally rare conditions, voretigene neparvovec (Luxturna) and burosumab (Crysvita). These are the first drugs to be tested along the ultra-orphan pathway a new approach...

Feb 10, 2020: Zealand Pharma, a biotechnology company focused on the discovery and development of the innovative peptide-based medicines, announces a bid in order...

Feb 9, 2020: Indian Pharma firms are closely monitoring the outbreak of the coronavirus in China as it could impact the supply of active pharmaceutical ingredients...

Feb 07, 2020: Clariant Masterbatches has developed a novel chrome color that opens new opportunities for the designers and manufacturers of high-end products, bottles and packaging. Targeted...

Feb 6, 2020: Amarin Corporation plc announced that BioNJ awarded Amarin with an Innovator Award in recognition of the approval of a new indication...

Feb 5, 2020: Nestlé Health Science and Valbiotis, a research and development company committed to scientific innovation for preventing and fighting metabolic diseases, have...

This blog has been written after discussion with many NIPER qualifiers. Even the Writer of this blog is Ex NIPERian. He got 56 Rank...

Feb 7, 2020: U.S. FDA authorized marketing of software to assist medical professionals in the acquisition of cardiac ultrasound, or echocardiography, images. This software, called...

Feb 6, 2020: Its primary endpoint was reached by the Sanofi Phase 2b trial evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral brain penetrating, selective small molecule. In the trial, as measured by the magnetic resonance imaging (MRI), SAR442168 significantly reduced disease activity associated despite multiple sclerosis (MS). With no new safety results, SAR442168 had been well accepted. The BTK inhibitor is deliberate to modulate both adaptive (B-cell activation) and innate (CNS microglial cells) immune cells linked to neuroinflammation in the...

Feb. 06, 2020: Aquestive Therapeutics, Inc, announced today that it had a constructive face-to-face pre-IND Application meeting with the U.S.FDA for its drug candidate,...